Price
Target price
€26.09
€26.09
1.280%
0.33
1.280%
-
04.10.24 / Tradegate
WKN: 853849 / Symbol: TKPHF / Name: Takeda Pharma / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Takeda Pharmaceutical Co Ltd Stock
Takeda Pharmaceutical Co Ltd gained 1.280% today.
Our community identified positive and negative aspects for Takeda Pharmaceutical Co Ltd stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Takeda Pharmaceutical Co Ltd stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Takeda Pharmaceutical Co Ltd in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Takeda Pharmaceutical Co Ltd vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Takeda Pharmaceutical Co Ltd | 1.280% | 1.320% | -2.686% | -6.286% | 0.539% | -6.185% | -16.177% |
Santen Pharmaceutical Corp Ltd. | 1.870% | 0.926% | -6.838% | 31.325% | 22.472% | -6.034% | -29.677% |
Chugai Pharmaceutical Co Ltd | -0.070% | -2.117% | -0.807% | 52.482% | 27.219% | 35.476% | - |
Kyowa Hakko Kirin Co. Ltd. | -0.630% | 0.000% | -20.101% | -0.625% | 7.432% | -48.039% | -10.169% |
Comments
News
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement